Mainz Biomed and Moderna Inc have made significant advancements in cancer treatment through the use of mRNA technology. Mainz Biomed has developed a colorectal cancer screening test that has shown promising results in early cancer detection. With a 92% detection rate for colorectal cancer and 82% sensitivity for advanced adenomas, the test has the potential to revolutionize cancer diagnostics.
On the other hand, Moderna Inc and Merck & Co have collaborated to develop an experimental mRNA vaccine for cancer treatment in combination with Merck’s immunotherapy drug Keytruda. Their mid-stage trial results have shown a 96% overall survival rate in patients diagnosed with melanoma, demonstrating the potential of mRNA technology in revolutionizing cancer treatment.
Cancer is a complex disease with over 200 different types, making it challenging to find a cure. However, with the emergence of mRNA technology, there is hope for more effective and personalized cancer treatment options. The collaboration between Mainz Biomed and Moderna Inc/Merck & Co represents a turning point in cancer treatment, giving pharmaceutical companies the tools they need to redefine how cancer is treated.
Source
Photo credit finance.yahoo.com
